Atherosclerosis Market Expected to Expand Significantly Through 2034, Featuring Key Players Like Janssen, Genentech, BioInvent International AB, GlaxoSmithKline, Merck Sharp & Dohme LLC, Archer Research, Cardionovum GmbH, and Smarly | DelveInsight

Atherosclerosis, a chronic and progressive cardiovascular condition marked by the buildup of plaque within arterial walls, remains a leading cause of heart attacks, strokes, and peripheral vascular disease worldwide. Despite advances in lipid-lowering therapies and cardiovascular risk management, atherosclerosis continues to impose a substantial clinical and economic burden, especially in aging populations and individuals with comorbidities like diabetes and hypertension.

DelveInsight's latest report, "Atherosclerosis - Market Insight, Epidemiology and Market Forecast - 2034," offers a detailed analysis of the disease landscape, covering patient segmentation by plaque type, risk stratification, and treatment history across key markets-the US, EU4 (Germany, France, Italy, Spain), the UK, and Japan.

While statins and PCSK9 inhibitors dominate current treatment paradigms, the emergence of novel therapies, such as anti-inflammatory agents (e.g., ziltivekimab), RNA-based lipid regulators, and therapies targeting lipoprotein(a) and triglyceride-rich lipoproteins, are reshaping the future of atherosclerosis management. These innovations are aimed at addressing residual cardiovascular risk and improving long-term outcomes beyond LDL-C reduction.

The atherosclerosis market is projected to experience sustained growth through 2034, fueled by the increasing prevalence of cardiovascular risk factors, advancements in diagnostic technologies, and the launch of next-generation therapeutics. Additionally, greater emphasis on personalized medicine, earlier intervention, and combination therapy strategies is expected to further drive market expansion.

DelveInsight anticipates a rapidly evolving market landscape with expanding treatment options, rising disease awareness, and strong pipeline momentum, positioning the atherosclerosis market for multi-billion-dollar growth by 2034.

Request a sample and uncover the latest breakthroughs shaping the atherosclerosis market landscape and future outlook @ https://www.delveinsight.com/sample-request/atherosclerosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Some of the key insights of the Atherosclerosis Market Report:
• The atherosclerosis drugs market is projected to grow at a steady CAGR throughout the forecast period from 2024 to 2034.
• Atherosclerosis is a chronic inflammatory disease of the arteries and is the underlying cause of nearly 50% of all deaths in Western societies.
• In the US, approximately 610K people die annually from heart disease.
• About 75% of acute myocardial infarctions in the US are caused by plaque rupture.
• Atherosclerosis shows a higher prevalence in men than in women, likely due to the protective role of female sex hormones, which decline after menopause.
• In high-income countries, the age-specific prevalence of peripheral artery disease (PAD) ranges from ~5% at ages 40-49 to ~13% at ages 70-79.
• In May 2025, Repair Biotechnologies announced that the FDA granted Orphan Drug Designation to its lead candidate, REP-0003, for the treatment of homozygous familial hypercholesterolemia (HoFH)-a rare disorder that causes accelerated atherosclerosis. REP-0003 is being developed to rapidly reduce atherosclerotic plaque, offering a novel approach to treating severe lipid-driven cardiovascular disease.
• In April 2025, Verve Therapeutics reported positive initial results from its Phase Ib Heart-2 trial of VERVE-102 in patients with HeFH and/or premature coronary artery disease (CAD). The gene-editing therapy was well-tolerated with no serious adverse events. A single infusion led to dose-dependent reductions in PCSK9 and LDL-C, with up to 69% LDL-C reduction observed at the highest dose.
• In February 2025, LIB Therapeutics announced that the FDA has accepted its Biologics License Application for Lerodalcibep, a third-generation PCSK9 inhibitor designed to lower LDL-C in patients with ASCVD, high-risk ASCVD, and primary hyperlipidemia, including HeFH and HoFH (ages 10+). The once-monthly, self-administered injection offers a patient-friendly alternative to existing treatments. The FDA set a PDUFA action date of December 12, 2025, and does not plan to hold an advisory committee meeting.
• In January 2025, the FDA granted 510(k) clearance to Roche's Tina-quant® Lipoprotein (a) Gen.2 Molarity assay. This marks the first blood test in the US cleared to measure lipoprotein (a) [Lp(a)] in molar units. The assay can aid in evaluating lipid metabolism disorders and assessing atherosclerotic cardiovascular disease (ASCVD) risk when used alongside clinical assessments and other lipoprotein tests.
• In January 2025, Cyclarity Therapeutics began its first-in-human Phase I trial of UDP-003, a novel therapy designed to remove arterial plaques and target atherosclerosis. The trial is being conducted at CMAX in Australia, in collaboration with Monash University and led by Dr. Stephen Nicholls, aiming to advance treatment for cardiovascular disease, the world's leading cause of death.
• Emerging therapies for atherosclerosis include Olpasiran, Obicetrapib, Zerlasiran, Glipizide, Rosuvastatin, Olmesartan medoxomil, Ateronon, Aliskiren, Canakinumab, Darapladib, Rimonabant, Ezetimibe, Lovastatin, and others.
• Key companies involved in the treatment of atherosclerosis include Janssen, Genentech, BioInvent International AB, GlaxoSmithKline, Merck Sharp & Dohme LLC, Archer Research, Cardionovum GmbH, Sankyo Pharma GmbH, Daiichi Sankyo, AstraZeneca, Omicron Pharmaceuticals, Abbott, Sanofi, Pfizer, and others.

To know in detail about the atherosclerosis market outlook, drug uptake, treatment scenario, and epidemiology trends, click here: https://www.delveinsight.com/report-store/atherosclerosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Atherosclerosis Overview
Atherosclerosis is a chronic cardiovascular condition marked by the buildup of plaque within the arterial walls. This progressive disease often begins in childhood and develops slowly over time, eventually leading to the hardening and narrowing of the arteries. It plays a central role in the onset of major cardiovascular events such as heart attacks, strokes, and other related complications.

The disease typically remains silent in its early stages, with symptoms emerging only when blood flow becomes significantly restricted. Key risk factors include high blood pressure, elevated LDL cholesterol, smoking, diabetes, obesity, physical inactivity, and a family history of heart disease.

Atherosclerosis starts when the inner lining of the arteries (endothelium) becomes damaged. This triggers an inflammatory response, causing fats, cholesterol, and cellular debris to accumulate and form plaques. As these plaques grow, they can obstruct blood flow or rupture, leading to clot formation. Such events can result in acute cardiovascular crises, depending on the location, such as a myocardial infarction (heart attack) or a stroke.

Common symptoms in advanced stages include chest pain (angina), shortness of breath, fatigue, and organ-specific symptoms like leg pain during walking in peripheral artery disease.

Get a free sample for the atherosclerosis market forecast, size & share analysis report: https://www.delveinsight.com/sample-request/atherosclerosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Atherosclerosis Epidemiology
The epidemiology section offers an overview of historical, current, and projected trends in the seven major countries (7MM) from 2020 to 2034. It helps identify the factors influencing these trends by examining various studies and perspectives from key opinion leaders. Additionally, the section provides an in-depth analysis of the diagnosed patient population and future trends.

Atherosclerosis Epidemiology Segmentation:
The atherosclerosis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM, segmented into:
• Total Prevalent cases
• Total Diagnosed Prevalent Cases
• Type-specific Diagnosed Prevalent Cases
• Gender-specific Diagnosed Prevalent Cases
• Age-specific Diagnosed Prevalent Cases

Atherosclerosis Drugs Uptake and Pipeline Development Activities
The Drug Uptake section offers a detailed analysis of the adoption trends of newly launched and upcoming therapies for Atherosclerosis throughout the study period. It evaluates patient adoption rates, market penetration, and the commercial performance of each therapy, providing a clear understanding of the factors driving or hindering the market acceptance of these treatments.

The Therapeutics Assessment further highlights the Atherosclerosis drugs, demonstrating the most rapid uptake. It examines the underlying drivers contributing to their swift adoption and compares the market share of these therapies to identify those gaining significant traction.

Additionally, the report provides an in-depth overview of the current therapeutic pipeline for Atherosclerosis, covering investigational drugs at various stages of development. It profiles the key pharmaceutical and biotech companies actively involved in advancing targeted treatments and presents the latest updates on partnerships, mergers and acquisitions, licensing deals, and other strategic developments shaping the future of Atherosclerosis therapeutics.

Explore how emerging atherosclerosis therapies are aligning with evolving patient populations @ https://www.delveinsight.com/report-store/atherosclerosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Atherosclerosis Market Outlook
The atherosclerosis therapeutics market is poised for steady growth over the forecast period (2024-2034), driven by the rising global prevalence of cardiovascular diseases, increasing awareness of risk factors, technological advancements in diagnostics and treatment, and the ongoing development of novel therapeutic options.

Treatment strategies for atherosclerosis are primarily aimed at halting the progression of arterial plaque buildup, improving vascular health, and reducing the risk of life-threatening complications such as heart attacks and strokes. While lifestyle modification-including a heart-healthy diet, regular exercise, smoking cessation, and weight management-remains a cornerstone of disease prevention and control, the market is largely supported by pharmacological therapies and interventional procedures.

The current therapeutic landscape includes a range of FDA-approved medications, such as statins, antiplatelet agents, antihypertensives, and blood sugar-lowering drugs. In recent years, innovation in lipid-lowering therapies has been notable. Novartis' LEQVIO (inclisiran), approved in 2021, introduced a new class of siRNA-based treatments, requiring only two doses annually, offering enhanced compliance and outcomes. Earlier approvals, including NEXLIZET and NEXLETOL (2020), have also expanded options for patients with established atherosclerotic cardiovascular disease who need additional LDL-C reduction.

In addition, the market is witnessing advancements in precision diagnostics. Companies like Ischemia Care LLC are transforming stroke risk assessment through technologies like the ISCDx test, which leverages gene expression profiling to rapidly distinguish between cardioembolic and atherosclerotic stroke causes. Such diagnostic innovations support personalized treatment approaches, further boosting the adoption of targeted therapeutics.

As the demand for improved cardiovascular outcomes grows, the pipeline of emerging therapies focused on lipid regulation, inflammation modulation, and plaque stabilization is expected to diversify the treatment paradigm. According to DelveInsight, the atherosclerotic cardiovascular disease market across the 7MM (the US, EU4, the UK, and Japan) is set to undergo significant changes during the forecast period, fueled by clinical progress, increased disease awareness, and expanded treatment accessibility.

With a comprehensive ecosystem of lifestyle interventions, approved drugs, cutting-edge diagnostics, and a robust late-stage pipeline, the atherosclerosis market holds strong potential to evolve into a multi-billion-dollar opportunity by 2034, offering hope for better long-term management and reduced cardiovascular mortality worldwide.

Atherosclerosis Market Drivers
• Increasing cases of atherosclerosis due to lifestyle changes, aging populations, and growing risk factors such as obesity, diabetes, and hypertension are driving demand for effective treatments.
• The development of novel lipid-lowering drugs, including siRNA therapies like inclisiran, and improved diagnostic tools enabling early and precise detection are accelerating market growth.

Atherosclerosis Market Barriers
• The expensive nature of some advanced therapies and diagnostic procedures may limit patient access, especially in low- and middle-income regions, restraining market expansion.
• Many patients remain undiagnosed or receive treatment late due to asymptomatic progression of atherosclerosis, impacting timely intervention and slowing market uptake of new therapies.

Scope of the Atherosclerosis Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan].
• Key Atherosclerosis Companies: Janssen, Genentech, BioInvent International AB, GlaxoSmithKline, Merck Sharp & Dohme LLC, Archer Research, Cardionovum GmbH, Sankyo Pharma GmbH, Daiichi Sankyo, AstraZeneca, Omicron Pharmaceuticals, Abbott, Sanofi, Pfizer, and others.
• Key Atherosclerosis Therapies: Olpasiran, Obicetrapib, Zerlasiran, Glipizide, Rosuvastatin, Olmesartan medoxomil, Ateronon, Aliskiren, Canakinumab, Darapladib, Rimonabant, Ezetimibe, Lovastatin, and others.
• Atherosclerosis Therapeutic Assessment: Atherosclerosis currently marketed, and Atherosclerosis emerging therapies.
• Atherosclerosis Market Dynamics: Atherosclerosis market drivers and Atherosclerosis market barriers.
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies.
• Atherosclerosis Unmet Needs, KOL's views, Analyst's views, Atherosclerosis Market Access and Reimbursement.

To learn more about atherosclerosis companies working in the treatment market, visit @ https://www.delveinsight.com/sample-request/atherosclerosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Atherosclerosis Market Report Introduction
2. Executive Summary for Atherosclerosis
3. SWOT analysis of Atherosclerosis
4. Atherosclerosis Patient Share (%) Overview at a Glance
5. Atherosclerosis Market Overview at a Glance
6. Atherosclerosis Disease Background and Overview
7. Atherosclerosis Epidemiology and Patient Population
8. Country-Specific Patient Population of Atherosclerosis
9. Atherosclerosis Current Treatment and Medical Practices
10. Atherosclerosis Unmet Needs
11. Atherosclerosis Emerging Therapies
12. Atherosclerosis Market Outlook
13. Country-Wise Atherosclerosis Market Analysis (2020-2034)
14. Atherosclerosis Market Access and Reimbursement of Therapies
15. Atherosclerosis Market Drivers
16. Atherosclerosis Market Barriers
17. Atherosclerosis Appendix
18. Atherosclerosis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.